About Us

Driven by science, we develop drugs to improve the lives of those with complex, life-altering diseases.

Our Mission

Our mission is to develop new treatments that address what matters most to patients. We are starting with MELAS and other genetic mitochondrial diseases. We believe we can enable a better future for patients and their loved ones.

Our Team

Our agile team of industry veterans is committed to developing innovative drugs that improve people’s lives. Our dedication to patients, our perseverance, and our passion for advancing Tisento’s mission unite our team.

Meet Our Team!

Fabien Boulineau, PhD
Director, Analytical
Development

Jennifer Chickering, PhD
Vice President,
Program Leadership

Chad Glasser, PharmD, MPH
Senior Director,
Clinical Research

Sara Hagmeier, MBA
Senior Director,
Finance and Operations

Peter Hecht, PhD
Chief Executive Officer

Jennifer King, PharmD
Senior Director, Clinical
Pharmacology, DMPK, and Toxicology

Bill Kissel, PhD
Vice President,
Pharmaceutical Operations

Todd Milne, PhD
Chief Operating Officer

Marian Rafferty
Chief of Staff

Wheatley Spence, MS
Head of Regulatory Affairs

Marta Cavero Tomas, PhD
Vice President, Intellectual Property, Contracts, and Licensing

Matt Webster, MS
Vice President,
Clinical Operations

Board of Directors

We have an engaged, top-notch Board of Directors who offer strategic guidance and valuable insights.

Paulina Hill
Sanofi Ventures
Board Member

Bryan Roberts
Venrock
Board Member

Peter Hecht, PhD
Tisento
Board Member

Our Network

We work closely with an extensive, global network of trusted advisors, thought leaders, patient advocacy groups, and other collaborators who are partners in our mission. This network complements our focused team, and together we are able to move quickly and tackle big goals on behalf of patients.

We collaborate with leading clinicians at mitochondrial disease centers of excellence around the world. These experts partner with us on our drug development programs and are instrumental in the execution of our clinical studies.

We deeply value our relationships with patient advocacy organizations who provide essential perspectives and connections with the patient communities we serve. We are proud to support their vital work and are grateful for the many ways they amplify the voices of patients.